| News

New at Switzerland Innovation Park Basel Area: SunRegen

05.03.2019

The biopharmaceutical company SunRegen Healthcare develops a therapy for neurodegenerative eye diseases like Optic Atrophy. The two co-founders and managers Dr. Yuhong Dong and Mr. David Guan moved their young startup to the Switzerland Innovation Park Basel Area in Allschwil in January 2019.

Yuhong Dong and David Guan, SunRegen Healthcare

In 2020 they hope to reach the next milestone and move their project from preclinical to clinical stage for their lead compound SBC003. This synthetic molecule is derived from a natural active ingredient that can be found in a medical herb used in the oriental medicine. Yuhong and David plan to test their compound for ALS as another target indication. Further, they want to test SBC003 for other neurological and neuromuscular diseases such as Alzheimer’s, Parkinson’s or Huntington’s disease.

At the Switzerland Innovation Park Basel Area in Allschwil, the co-founders concentrate on developing their business. They are especially happy that they were able to move in and start working right from the beginning, thanks to the furnished office. To host visitors, they appreciate the coffee area that is open to all residents as well as the meeting rooms the Switzerland Innovation Park Basel Area offers. “Even before we could afford an office, the team at the Switzerland Innovation Park was very forthcoming. They are always very friendly – we really enjoy being here.”

SunRegen Healthcare is one of the participants of the first round of the BaseLaunch accelerator. Back in 2017, Yuhong and David reached Phase I of the program, benefitting from customized coaching and funding for three months. Although they were not selected for phase II, they persisted in building their startup. In 2018, they won the BIO-Europe 2018 Startup Slam Competition, held in Copenhagen and gained access to a top-tier mentoring program with industry experts from Johnson & Johnson.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

VectivBio secures investments totaling 110 million dollars
Basel Area Business & Innovation, Innovation, Invest

VectivBio secures investments totaling 110 million dollars

The Basel-based biotechnology firm VectivBio has received a capital injection of 110 million US dollars from both new and existing...

Read More
Polyphor receives up to 18 million dollars for development of antibiotics
Basel Area Business & Innovation, Innovation, Invest

Polyphor receives up to 18 million dollars for development of antibiotics

The Allschwil-based company Polyphor has received a second funding award from the global consortium CARB-X to combat antimicrobial resistance. Polyphor...

Read More
What makes Switzerland’s economy resilient in face of COVID pandemic
Basel Area Business & Innovation, Invest

What makes Switzerland’s economy resilient in face of COVID pandemic

The COVID-19 pandemic has hit economies worldwide – and we have not yet overcome it. However, Switzerland is among the...

Read More
DayOne Accelerator applications open
Basel Area Business & Innovation, Innovation

DayOne Accelerator applications open

We are excited to announce the opening of the call for the DayOne Accelerator, now in its 3rd year!

Read More
Matériaux Sabag printing concrete elements
Basel Area Business & Innovation, Innovation, Invest

Matériaux Sabag printing concrete elements

The Jura-based company Matériaux Sabag is now using a 3D printing solution to produce its concrete elements. This approach allows...

Read More
Six companies win the i4Challenge
Basel Area Business & Innovation, Innovation

Six companies win the i4Challenge

The i4Challenge expert jury has selected six winners from 18 finalists. The Industry 4.0 solutions range from 3D printing, IoT,...

Read More
Monte Rosa Therapeutics banks 96 million US dollars
Basel Area Business & Innovation, Innovation, Invest

Monte Rosa Therapeutics banks 96 million US dollars

The Basel-based biotechnology firm Monte Rosa Therapeutics has raised a total of 96 million US dollars after closing a successful...

Read More
Roche launches new coronavirus antibody test
Basel Area Business & Innovation, Innovation, Invest

Roche launches new coronavirus antibody test

Roche is launching on the market a new antibody test to determine coronavirus infections. This should help with the development...

Read More
Investors see great potential in Polyneuron
Basel Area Business & Innovation, Innovation, Invest

Investors see great potential in Polyneuron

The Basel-based company Polyneuron Pharmaceuticals extended its Series A funding round and has now raised a total of 36.5 million...

Read More
Lonza set to manufacture coronavirus drug for Humanigen
Basel Area Business & Innovation, Innovation, Invest

Lonza set to manufacture coronavirus drug for Humanigen

The Basel-based pharmaceutical supplier Lonza is supporting the US firm Humanigen in the development of a potential coronavirus therapeutic. Lonza...

Read More
1 2 3 21

Do you have a question? We'd like to hear from you.